Drug Trial Radar · NCT06683612
PET Study of PIPE-791 in Healthy Volunteers and Volunteers With PrMS and IPF
Last checked: Nov 19, 2026Latest source record: Aug 6, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
16
Actual
Start
Dec 9, 2024
Primary completion
Jun 4, 2025
Study completion Jun 12, 2025
Sponsor
- Lead sponsor
- Contineum TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Nov 12, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 25 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a study of PIPE-791, an investigational study drug to treat progressive multiple sclerosis (MS) and idiopathic pulmonary fibrosis (IPF). The purpose of this study is to find out how much of the study drug gets into the brain and lung, and what the side effects and blood levels of the study drug are in healthy volunteers and patients. Participants will: * Take a single dose of the study drug * Give many samples of blood and urine * Have multiple PET scans
Conditions
- Idiopathic Pulmonary Fibrosis (IPF)
- Idiopathic Pulmonary Fibrosis
- Multiple Sclerosis
- Multiple Sclerosis, MS
- Multiple Sclerosis, Primary Progressive
- Multiple Sclerosis, Progressive
- Multiple Sclerosis, Secondary Progressive
- Healthy
- Healthy Volunteers
Interventions
PIPE-791Drug
Subjects will receive a single oral dose of PIPE-791.
Primary outcomes
What the sponsor says the trial is designed to measure.
- LPA1 occupancy as determined by regional total volume of distribution (VT) at each brain scan.Time frame: Baseline to up to 28 days post-dose
- LPA1 occupancy as determined by regional total volume of distribution (VT) at each lung scan.Time frame: Baseline to up to 28 days post-dose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Hammersmith Medicines Research
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.